fwd1802
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2023 (NCT06064812)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorDEGRADER
Estrogen receptor degrader
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07002177 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2025 | Forward Pharmaceuticals Co., Ltd. |
| NCT06064812 | Phase 1 | Sep 12, 2023 | Forward Pharmaceuticals Co., Ltd., Fudan University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forward Pharmaceuticals Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1